CDK6 and pancreatic adenocarcinoma: To verify the cancer-promoting effect of CDK6 in four tumors (ACC, CESC, LGG, and PAAD), Kaplan–Meier survival analysis was used to determine that CDK6 is not beneficial for patient prognosis and the ROC curve was used to characterize the relationship between the expression level of CDK6 and the prognosis—that is, the accuracy of the CDK6 model used to evaluate the survival of tumor patients.